Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD 0.08.

EBIT: As of FY2025 Q3, the actual value is USD -3.526 M.

Segment Revenue

• Investment Income from Trust Account: For the three months ended September 30, 2025, investment income was $3,343,285, and for the nine months ended September 30, 2025, it was $5,427,225.

Operational Metrics

• General and Administrative Expenses: For the three months ended September 30, 2025, expenses were $179,492, and for the nine months ended September 30, 2025, expenses were $426,577.
• Net Income: For the three months ended September 30, 2025, net income was $3,167,377, and for the nine months ended September 30, 2025, net income was $5,010,826.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used was - $1,268,544.
• Net Cash Used in Investing Activities: For the nine months ended September 30, 2025, net cash used was - $300,150,000.
• Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided was $301,709,510.

Unique Metrics

• Trust Account Balance: As of September 30, 2025, investments held in the Trust Account amounted to $305,577,225.

Future Outlook and Strategy

• Core Business Focus: The company is strategically positioned to capitalize on transformative opportunities, focusing on sectors pivotal to advancing sustainability and innovation, with a keen interest in new energy businesses, circular economy initiatives, and innovative agricultural and food technologies.
• Non-Core Business: The company has entered into a non-binding letter of intent with OnMed LLC for a potential business combination, with expectations to announce additional details if and when a definitive agreement is executed.